scispace - formally typeset
Open AccessJournal ArticleDOI

Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry.

TLDR
Hyponatraemia in hospitalized patients with heart failure is relatively common and is associated with longer hospital stays and higher in-hospital and early post-discharge mortality.
Abstract
Aims Hyponatraemia has been shown to be an independent predictor of mortality in selected patients with heart failure enrolled in clinical trials. The predictive value of hyponatraemia has not been evaluated in unselected patients hospitalized with heart failure. Methods and results OPTIMIZE-HF is a registry and performance-improvement programme for patients hospitalized with heart failure and includes a subgroup with 60–90 day follow-up data. The relationship between admission serum sodium concentration and clinical outcomes was analysed in 48 612 patients from 259 hospitals. Admission serum sodium levels were analysed both as a continuous variable and by grouping patients with admission Na <135 and Na ≥ 135 mmol/L. Patients with hyponatraemia (Na <135 mmol/L) at the time of hospital admission had modest differences in baseline clinical characteristics and management during hospitalization compared with patients who had serum sodium ≥135 mmol/L. Patients with hyponatraemia were more likely to be Caucasian, have lower admission systolic blood pressure, and receive intravenous inotropes during hospitalization. Patients with hyponatraemia had significantly higher rates of in-hospital and follow-up mortality and longer hospital stays, although no difference in re-admission rates was observed. After adjusting for differences with multivariable analysis, the risk of in-hospital death increased by 19.5%, the risk of follow-up mortality by 10%, and the risk of death or rehospitalization by 8% for each 3 mmol/L decrease in admission serum sodium below 140 mmol/L. Conclusion Hyponatraemia in hospitalized patients with heart failure is relatively common and is associated with longer hospital stays and higher in-hospital and early post-discharge mortality. Re-admission rates were equally high in patients with or without hyponatraemia.

read more

Citations
More filters
Journal ArticleDOI

Narrative review: the management of acute decompensated heart failure.

TL;DR: Evidence-based recommendations are provided for the diagnosis and management of acute decompensated heart failure including morphine, high-dose diuretics, and inotropic agents may be harmful.
Journal ArticleDOI

The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries.

TL;DR: Global HHF registries are reviewed to describe the patient characteristics, management, outcomes and their predictors, quality improvement initiatives, regional differences, and limitations of the available data and propose a roadmap for the design and conduct of future H HF registries.
Journal ArticleDOI

Clinical practice guideline on diagnosis and treatment of hyponatraemia

TL;DR: The Clinical Practice Guideline on the diagnostic approach and treatment of hyponatraemia is developed as a joint venture of three societies representing specialists with a natural interest in hyponatonemia to obtain a common and holistic view.
References
More filters
Journal ArticleDOI

Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model.

TL;DR: Among community-based heart failure patients, factors identifiable within hours of hospital presentation predicted mortality risk at 30 days and 1 year, and the externally validated predictive index may assist clinicians in estimating heart failure mortality risk and in providing quantitative guidance for decision making in heart failure care.
Journal ArticleDOI

Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.

TL;DR: In patients with euvolemic or hypervolemic hyponatremia, tolvaptan, an oral vasopressin V2-receptor antagonist, was effective in increasing serum sodium concentrations at day 4 and day 30.
Journal ArticleDOI

Representation of the elderly, women, and minorities in heart failure clinical trials.

TL;DR: Comparing the characteristics of patients in heart failure (HF) RCTs with those of patients with HF in the community, and to document these trends over time, did not find a significant improvement in the representation of the trials.
Related Papers (5)